Flexion Therapeutics Stock Forecast, Price & News

-0.14 (-1.58 %)
(As of 06/23/2021 12:57 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume10,197 shs
Average Volume796,988 shs
Market Capitalization$435.49 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive FLXN News and Ratings via Email

Sign-up to receive the latest news and ratings for Flexion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Flexion Therapeutics logo

About Flexion Therapeutics

Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.76 out of 5 stars

Medical Sector

227th out of 2,105 stocks

Pharmaceutical Preparations Industry

111th out of 832 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions

Is Flexion Therapeutics a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last twelve months. There are currently 1 hold rating, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Flexion Therapeutics stock.
View analyst ratings for Flexion Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Flexion Therapeutics?

Wall Street analysts have given Flexion Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Flexion Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Flexion Therapeutics' next earnings date?

Flexion Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Flexion Therapeutics

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced its earnings results on Wednesday, May, 12th. The specialty pharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.49) by $0.08. The specialty pharmaceutical company earned $24.59 million during the quarter, compared to analyst estimates of $24.61 million.
View Flexion Therapeutics' earnings history

How has Flexion Therapeutics' stock been impacted by COVID-19?

Flexion Therapeutics' stock was trading at $12.31 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FLXN shares have decreased by 29.2% and is now trading at $8.72.
View which stocks have been most impacted by COVID-19

What guidance has Flexion Therapeutics issued on next quarter's earnings?

Flexion Therapeutics updated its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided earnings per share (EPS) guidance of $- for the period. The company issued revenue guidance of $120 million-130 million, compared to the consensus revenue estimate of $133.77 million.

What price target have analysts set for FLXN?

10 brokerages have issued twelve-month target prices for Flexion Therapeutics' shares. Their forecasts range from $14.00 to $35.00. On average, they expect Flexion Therapeutics' share price to reach $20.13 in the next twelve months. This suggests a possible upside of 130.8% from the stock's current price.
View analysts' price targets for Flexion Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Flexion Therapeutics' key executives?

Flexion Therapeutics' management team includes the following people:
  • Dr. Michael D. Clayman, Co-Founder, Pres, CEO & Director (Age 69, Pay $1.13M)
  • Mr. David A. Arkowitz M.B.A., Chief Financial Officer (Age 60, Pay $697.52k)
  • Scott Young, VP of Corp. Communications & Investor Relations
  • Ms. Carolyn Beaty Scimemi, VP, Legal Affairs & Chief Compliance Officer
  • Mr. Mark S. Levine, Gen. Counsel & Corp. Sec. (Age 48)
  • Dr. Neil Bodick, Consultant (Age 74)
  • Ms. Christina Willwerth, Chief Strategy Officer (Age 50)
  • Ms. Kerry A. Wentworth, Chief Regulatory Officer (Age 48)
  • Dr. Adam L. Muzikant Ph.D., Chief Bus. Officer (Age 50)
  • Ms. Melissa Layman, Chief Commercial Officer (Age 52)

What is Mike Clayman, MD's approval rating as Flexion Therapeutics' CEO?

46 employees have rated Flexion Therapeutics CEO Mike Clayman, MD on Mike Clayman, MD has an approval rating of 85% among Flexion Therapeutics' employees.

Who are some of Flexion Therapeutics' key competitors?

What other stocks do shareholders of Flexion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Aduro Biotech (ADRO), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and Verastem (VSTM).

What is Flexion Therapeutics' stock symbol?

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

Who are Flexion Therapeutics' major shareholders?

Flexion Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.04%), Wasatch Advisors Inc. (8.43%), Artisan Partners Limited Partnership (6.30%), Clearline Capital LP (2.81%), Versant Venture Management LLC (2.62%) and Goldman Sachs Group Inc. (2.04%). Company insiders that own Flexion Therapeutics stock include Adam Muzikant, David Arkowitz, Mark S Levine, Mark Stejbach, Melissa Layman, Michael D Clayman and Samuel D Colella.
View institutional ownership trends for Flexion Therapeutics

Which major investors are selling Flexion Therapeutics stock?

FLXN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Credit Suisse AG, Versant Venture Management LLC, Russell Investments Group Ltd., American Financial Group Inc., Royce & Associates LP, Northern Trust Corp, and Nuveen Asset Management LLC. Company insiders that have sold Flexion Therapeutics company stock in the last year include Adam Muzikant, David Arkowitz, Mark S Levine, and Melissa Layman.
View insider buying and selling activity for Flexion Therapeutics
or view top insider-selling stocks.

Which major investors are buying Flexion Therapeutics stock?

FLXN stock was bought by a variety of institutional investors in the last quarter, including Clearline Capital LP, Goldman Sachs Group Inc., JPMorgan Chase & Co., BlackRock Inc., Millennium Management LLC, Citigroup Inc., GAM Holding AG, and Jane Street Group LLC. Company insiders that have bought Flexion Therapeutics stock in the last two years include Mark Stejbach, Michael D Clayman, and Samuel D Colella.
View insider buying and selling activity for Flexion Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Flexion Therapeutics?

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Flexion Therapeutics' stock price today?

One share of FLXN stock can currently be purchased for approximately $8.72.

How much money does Flexion Therapeutics make?

Flexion Therapeutics has a market capitalization of $435.49 million and generates $85.55 million in revenue each year. The specialty pharmaceutical company earns $-113,710,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis.

How many employees does Flexion Therapeutics have?

Flexion Therapeutics employs 257 workers across the globe.

What is Flexion Therapeutics' official website?

The official website for Flexion Therapeutics is

Where are Flexion Therapeutics' headquarters?

Flexion Therapeutics is headquartered at 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803.

How can I contact Flexion Therapeutics?

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]

This page was last updated on 6/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.